Improved survival in pediatric umbilical cord transplants for hematologic cancers
Umbilical cord blood, a rich source of blood-forming stem cells, has previously been shown to benefit many patients with leukemia and myelodysplasia and other diseases, including bone marrow failure syndromes, hemoglobinopathies, inherited immune ...
Oncology Nurse Advisor - Mon, 24 Nov 2014 06:26



Anderson Provides Insight Into Novel Agents in Multiple Myeloma
The treatment of patients with multiple myeloma is poised to undergo a dramatic transformation, as novel monoclonal antibodies and combination strategies race toward approval. To gain insight into this rapidly changing treatment environment, OncLive ...
OncLive - Wed, 26 Nov 2014 05:07

Clonal Hematopoiesis With Somatic Mutations Up With Age
The presence of somatic mutations correlated with increased risk of hematologic cancer, all-cause mortality, incident coronary heart disease, and ischemic stroke. Giulio Genovese, Ph.D., from the Broad Institute of the Massachusetts Institute of ...
Doctors Lounge - Wed, 26 Nov 2014 16:33

SLE Patients See Good Outcomes in Blood Cancers
Patients diagnosed with hematological malignancies before or concurrently with SLE in the study presented with earlier-stage disease and often achieved cancer remission, according to the report in Lupus Science and Medicine. SLE patients have been ...
MedPage Today - Mon, 24 Nov 2014 13:56

Spark Therapeutics Appoints Former Chief of U.S. Food and Drug ...
Spark plans to leverage its experience with SPK-RPE65 to address a broad spectrum of blinding conditions, and also has established a pipeline of gene therapy candidates to treat hematologic and neurodegenerative disorders. Spark's integrated gene ...
The Providence Journal - Tue, 25 Nov 2014 08:07

Portola Pharmaceuticals to Present at the Credit Suisse 2014 Healthcare ...
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel ...
Nasdaq - Thu, 06 Nov 2014 04:56

Exome Sequencing Studies Find Premalignant Mutations in Blood that Increase ...
The two research teams, which used cohorts that were originally collected for projects unrelated to cancer – one for type 2 diabetes research, the other for research into schizophrenia and bipolar disorder – published their studies online in the New ...
GenomeWeb - Wed, 26 Nov 2014 14:52



Early IDH1 Inhibitor Data Promising in AML
Hematologic Malignancy The IDH1 inhibitor AG-120 has shown a favorable safety and efficacy profile in patients with IDH1 mutation positive advanced hematologic malignancies, including acute myeloid leukemia (AML), according to early data from a phase I ...
OncLive - Mon, 24 Nov 2014 08:41


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014